Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04577807 · ClinicalTrials.gov registry record · Phase 2
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
A Phase 2 study, sponsored by Istari Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT04577807: Completed Phase 2 study, sponsored by Istari Oncology.
NCT04577807 is a Phase 2 study that has completed, run by Istari Oncology. The registered enrollment target is 27 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04577807, a Phase 2 study, has completed, sponsored by Istari Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
A Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibitor.
Primary Outcome
The number of patients achieving confirmed complete (CR) or partial response (PR), per RECIST 1.1 criteria
Interventions
- BIOLOGICAL Lerapolturev
- BIOLOGICAL Anti-PD-1 Checkpoint Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-11-17 |
| Est. Completion | 2024-11-15 |
| Phase | Phase 2 |
What the finished NCT04577807 record still lists
NCT04577807 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Lerapolturev is the first listed.
NCT04577807 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04577807 about?
NCT04577807 is a clinical study titled "LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma". A Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibitor.
What is the current status of trial NCT04577807?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2020-11-17. Estimated completion is 2024-11-15.
What interventions are being tested in trial NCT04577807?
The interventions under investigation include: Lerapolturev (BIOLOGICAL), Anti-PD-1 Checkpoint Inhibitor (BIOLOGICAL).
Who is sponsoring clinical trial NCT04577807?
This trial is sponsored by Istari Oncology, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04577807's enrollment target sits among peer trials
27 1697th of 2000 higher than 293 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI